Drug
GW273225
GW273225 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_1
2
67%
Ph phase_2
1
33%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Withdrawn1
Terminated1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
withdrawn133%
terminated133%
completed133%
Recent Activity
0 active trials
Showing 3 of 3
terminatedphase_1
Oral Contraceptive Interaction Study for GW273225
NCT00483535
completedphase_1
Study to Assess the Effect of Food on the Concentration of GW273225 in the Body of Healthy Male and Female Volunteers
NCT00501865
withdrawnphase_2
GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures
NCT00567424
Clinical Trials (3)
Showing 3 of 3 trials
NCT00483535Phase 1
Oral Contraceptive Interaction Study for GW273225
NCT00501865Phase 1
Study to Assess the Effect of Food on the Concentration of GW273225 in the Body of Healthy Male and Female Volunteers
NCT00567424Phase 2
GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3